Article
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Blood - 1 Nov 2004
Griswold Ian J, Shen Lei J, La Rosée Paul, Demehri Shadmehr, Heinrich Michael C, Braziel Rita M, McGreevey Laura, Haley Andrea D, Giese Neill, Druker Brian J, Deininger Michael W N
Abstract excerpt
Internal tandem duplications (ITDs) of the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase are found in approximately 30% of patients with acute myelogenous leukemia (AML) and are associated with a poor prognosis. FLT3 ITD mutations result in constitutive kinase activation and are thought to be pathogenetically relevant, implicating FLT3 as a plausible therapeutic target. MLN518 (formerly CT53518) is a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.